Clinical Trial Update: Study of HL-085 in NRAS Mutant Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for HL-085 in NRAS-mutant advanced melanoma (Phase 1/2) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• HL-085

Snippet

Sponsor: Shanghai Kechow Pharma, Inc. | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED